In vitro model of mycobacteria and HIV-1 co-infection for drug discovery.

[1]  Robert L. Hunter,et al.  A Humanized Mouse Model of Tuberculosis , 2013, PloS one.

[2]  S. A. Abdool Karim,et al.  When to start antiretroviral therapy during tuberculosis treatment? , 2013, Current opinion in infectious diseases.

[3]  Gundo Weiler,et al.  Global Update on HIV Treatment 2013: Results, Impact and Opportunities , 2013 .

[4]  Philippe Glaziou,et al.  Global tuberculosis control: lessons learnt and future prospects , 2012, Nature Reviews Microbiology.

[5]  Hong Liang,et al.  Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guérin , 2012, Journal of Nanobiotechnology.

[6]  D. Havlir,et al.  HIV and tuberculosis – science and implementation to turn the tide and reduce deaths , 2012, Journal of the International AIDS Society.

[7]  M. Marsden,et al.  HIV Latency in the Humanized BLT Mouse , 2011, Journal of Virology.

[8]  W. Baze,et al.  Antibacterial Role for Natural Killer Cells in Host Defense to Bacillus anthracis , 2011, Infection and Immunity.

[9]  Ning Zhang,et al.  Whole‐Body Imaging of Infection Using Fluorescence , 2011, Current protocols in microbiology.

[10]  D. Havlir,et al.  Tuberculosis as part of the natural history of HIV infection in developing countries. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Pai,et al.  Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Richard,et al.  HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. , 2010, Blood.

[13]  M. Wainberg,et al.  Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice , 2010, PloS one.

[14]  A. Hogg,et al.  Induction of granulysin in CD8+ T cells by IL‐21 and IL‐15 is suppressed by human immunodeficiency virus‐1 , 2009, Journal of leukocyte biology.

[15]  F. Kirchhoff,et al.  Is Nef the elusive cause of HIV-associated hematopoietic dysfunction? , 2008, The Journal of clinical investigation.

[16]  W. Waters,et al.  Mycobacterium bovis BCG vaccination induces memory CD4+ T cells characterized by effector biomarker expression and anti-mycobacterial activity. , 2007, Vaccine.

[17]  G. Maartens,et al.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. , 2007, The Journal of infectious diseases.

[18]  A. Walubo.  The role of cytochrome P450 in antiretroviral drug interactions. , 2007, Expert opinion on drug metabolism & toxicology.

[19]  M. E. Villarino.  Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations , 1998 .

[20]  A. Poggi,et al.  HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels. , 1998, Journal of immunology.

[21]  Y. Cao,et al.  Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. , 1997, American journal of respiratory and critical care medicine.

[22]  D. Hom,et al.  Accelerated course of human immunodeficiency virus infection after tuberculosis. , 1995, American journal of respiratory and critical care medicine.

[23]  H. Friedman,et al.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1 , 1992, Journal of virology.